Emelina Preis

Emelina Preis

Auto-generated profile, based on publicly available information

Emelina Preis

Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
CMChristine March
Christine March
DHDörte Huscher
Dörte Huscher
EPEmelina Preis
Emelina Preis
AMAlexander Makowka
Alexander Makowka
JHJakob Hoeppner
Jakob Hoeppner
ESElise Siegert
Elise Siegert
Thank you very much for your interest in our article “Prevalence of Depressive Symptoms in Patients with Systemic Sclerosis”. We value your contribution to central questions on prevalence and relevance of depressive disorders in this field and are glad to respond to your concerns. We are fully aware that the Major Depression Inventory (MDI) does not allow us to diagnose depressive disorders or to estimate its prevalence among patients with systemic sclerosis (SSc). At no point in our study did we claim that we assessed the prevalence of depression in SSc.[1] You might be right that the scientific value of estimating the prevalence of MDI-relevant items is limited. However, as we mention in the discussion of our paper, we want to raise the awareness for mental health issues in SSc without providing psychiatric diagnoses, measuring significant impairment or estimating the prevalence of depressive disorders in SSc. Also, we did not evaluate the MDI as a screening tool for depressive disorders in SSc. Our primary interest was to assess the number of patients suffering from depressive symptoms and who might thus benefit from systematic evaluation of mental health issues. We share your concerns regarding the overestimation of depressive disorders by depression symptom questionnaires. However, we chose the MDI because it is known to be a rather conservative measure for depressive symptoms according to comparative studies using other self-report questionnaires.[2] At the same time, it is short enough to be handed out to patients in an out-patient setting. Hence, it might potentially serve as a screening tool; to evaluate this was not the aim of your study. Of note, as mentioned in our paper, we were able to confirm a lower prevalence of these symptoms than stated in other studies.[3-9] This is in line with previous findings from Nielsen et al.[2] indicating that the MDI is a more conservative tool and which may support the idea that the MDI should be evaluated as a screening tool for depressive disorders in SSc.

1 June 2016 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
CMC. March
C. March
DHDörte Huscher
Dörte Huscher
AMA. Makowka
A. Makowka
EPE. Preis
E. Preis
FBF. Buttgereit
F. Buttgereit
ESElise Siegert
Elise Siegert
Background The development of depressive symptoms is very common among patients with Systemic Sclerosis (SSc).1 Objectives Evaluation of the prevalence of depressive symptoms among German SSc patients at our centre, identification of possible risk factors and analysis of the current standard of care in clinical settings. Methods 94 of 134 patients (82 women (87.2%), age 58.3 ± 13.6 years, BMI 24.5 ± 5.4 kg/m2) in our study met the inclusion criteria of matching the ACR/EULAR 2013 classification criteria, being at least 18 years old, able to consent and having completed the Major Depression Inventory (MDI), Short Form 36 (SF-36®), Scleroderma Health Assessment Questionnaire (SHAQ), Brief Fatigue Inventory (BFI) and Physical Activity Questionnaire (IPAQ). The prevalence of depressive symptoms was evaluated using the MDI. The identifying potential of patient questionnaires for the risk of an SSc patient to suffer from depressive symptoms was evaluated using the SF-36® for quality of life, the SHAQ for disability, the BFI for fatigue and the IPAQ for activity. Discharge letters of the time when the patients were included were analyzed regarding the assessment and treatment of depressive symptoms and mental health. Clinical and para clinical parameters were measured according to standardized procedures. The data were analyzed with IBM SPSS® Statistics by using Chi-Square/Fisher-, Mann-Whitney-U-test, correlation and regression analysis. Results The prevalence of depressive symptoms according to the MDI score ≥20 was 22.3%. In the analysis of risk factors between two subgroups (MDI Score <20 and MDI Score ≥20), underweight (BMI <18.5 kg/m2) turned out to be a significant risk factor (p=0.002) (Image 1). Also, there was a significant correlation between general health (SHAQ) (r=0.508, p=0.01), quality of life (SF 36®) (r= -0.769, p=0.01), fatigue (BFI) (r=0.721, p=0.01) and physical activity (IPAQ MET/min) (r= -0.331, p=0.01) with the level of the MDI score. The analysis of the current standard of care showed that the majority of the patients 84 (89.4%) were not assessed for depressive symptoms or mental health, including 19 with an MDI score ≥20. Mood disorders were diagnosed in 5 (5.3%) patients, 13 (13.8%) were treated with antidepressants and in 6 (6.4%) cases psychological intervention was carried out or suggested. Conclusions There is a high prevalence of depressive symptoms, which should be kept in mind when treating patients with SSc. Special attention should be paid to weight loss and fatigue, results in the SF-36®, SHAQ and IPAQ. The mental health should be assessed during consultations on a regular basis. The questionnaires applied in this study could be used as indicators for the risk of an SSc patient to suffer from depressive symptoms with the BFI and SF-36 being the most sensitive ones. Launay D, Baubet T, Cottencin O, Bérezné A, Zéphir H, Morell-Dubois S et.al., Atteintes neuropsychiatriques au cours de la sclérodermie systémique. La presse Médicale, 2010; 39:5 Disclosure of Interest None declared